SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-21-050089
Filing Date
2021-10-05
Accepted
2021-10-04 20:33:53
Documents
5
Period of Report
2021-11-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A srne-def14a_20211115.htm DEF 14A 1259396
2 GRAPHIC gi2wtqv4m5vy000003.jpg GRAPHIC 76560
3 GRAPHIC gi2wtqv4m5vy000002.jpg GRAPHIC 13479
4 GRAPHIC gi2wtqv4m5vy000004.jpg GRAPHIC 84874
5 GRAPHIC gi2wtqv4m5vy000001.jpg GRAPHIC 13479
  Complete submission text file 0001564590-21-050089.txt   1520493
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36150 | Film No.: 211304851
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences